Goldman Sachs Group Inc. cut shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) from a neutral rating to a sell rating in a research report released on Thursday. They currently have $16.00 target price on the stock, down from their prior target price of $23.00.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Several other equities research analysts have also recently commented on ATRA. JMP Securities reissued a buy rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a research report on Friday, September 2nd. Canaccord Genuity reissued a buy rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Jefferies Group reaffirmed a buy rating and issued a $25.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. Finally, Citigroup Inc. upped their target price on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a sell rating in a report on Friday, August 19th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of Hold and an average target price of $26.14.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 19.17 on Thursday. The company’s market capitalization is $552.31 million. The company has a 50 day moving average price of $21.49 and a 200 day moving average price of $19.99. Atara Biotherapeutics has a 12-month low of $13.31 and a 12-month high of $45.91.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.61) by $0.05. Equities analysts anticipate that Atara Biotherapeutics will post ($2.85) EPS for the current year.

In related news, insider Christopher Haqq sold 1,346 shares of the stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $22.32, for a total transaction of $30,042.72. Following the sale, the insider now owns 295,294 shares in the company, valued at approximately $6,590,962.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 9,600 shares of the stock in a transaction that occurred on Friday, July 8th. The stock was sold at an average price of $22.88, for a total transaction of $219,648.00. Following the sale, the chief executive officer now owns 223,228 shares in the company, valued at approximately $5,107,456.64. The disclosure for this sale can be found here. Corporate insiders own 16.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Group LTD raised its stake in shares of Atara Biotherapeutics by 76.8% in the first quarter. BlackRock Group LTD now owns 5,400 shares of the company’s stock worth $103,000 after buying an additional 2,345 shares in the last quarter. Barclays PLC raised its stake in shares of Atara Biotherapeutics by 2,266.0% in the second quarter. Barclays PLC now owns 4,803 shares of the company’s stock worth $108,000 after buying an additional 4,600 shares in the last quarter. BlackRock Inc. raised its stake in shares of Atara Biotherapeutics by 464.3% in the second quarter. BlackRock Inc. now owns 6,100 shares of the company’s stock worth $137,000 after buying an additional 5,019 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares in the last quarter. Finally, BlackRock Advisors LLC raised its stake in shares of Atara Biotherapeutics by 30.2% in the second quarter. BlackRock Advisors LLC now owns 10,186 shares of the company’s stock worth $229,000 after buying an additional 2,361 shares in the last quarter. Hedge funds and other institutional investors own 75.50% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

5 Day Chart for NASDAQ:ATRA

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.